Roche Holding AG (0QQ6)
London Exchange · UK · prices in GBP · close of 23 Oct 2026
Key indicators
| Last close | GBP 399.20 |
|---|---|
| 52-week range | 271.40 – 400.00 |
| Return, 1 month / 3 months | +6.4% / +12.3% |
| Return, 1 year / 3 years | +46.2% / +74.4% |
| Trend | Uptrend |
| RSI (14) | 72 |
| Volatility (1 year) | 23.2% |
| Worst drawdown (1 year) | -16.2% |
| Average daily value traded | 1.03M GBP |
| Dividend yield | 2.7% |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Roche Holding AG is a healthcare company based in Basel, Switzerland. It discovers, develops and sells prescription medicines, with a focus on cancer, immune disorders and diseases of the nervous system. The company also supplies diagnostic tests and laboratory instruments used by hospitals and clinics to detect and monitor illness. Its medicines and diagnostics are sold to healthcare providers and patients around the world, and the two sides of the business are run alongside each other.
The shares are listed on the London Exchange in UK under the code 0QQ6, and the price on this page is in pounds sterling (GBP). Our dividend records, which start in 2019, show payments in 8 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Roche Holding AG (0QQ6) trades on the London Exchange in UK. It last closed at GBP 399.20 on 23 October 2026.
Its price-based Market X-Ray is 74 out of 100 (a strong price profile), ranking 300 of 3,787 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price rose 46.2% and over the last three months it rose 12.3%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on London Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 84 · Strong | Trading above its long-term averages and near its highs. | |
| Above 200-day average | 14.9% | ||
| From 52-week high | 0.0% | ||
| Momentum | 81 · Strong | Rising faster than most stocks on this exchange. | |
| 3-month return | 12.3% | ||
| 6-month return | 19.8% | ||
| 12-month return, skipping the last month | 37.3% | ||
| Stability (higher is calmer) | 82 · Strong | Calmer than most: low volatility and shallow drawdowns. | |
| Volatility, 1 year (lower is calmer) | 23.2% | ||
| Worst drawdown, 1 year (smaller is calmer) | -16.2% | ||
| Liquidity | 53 · Fair | Moderate trading activity. | |
| Average daily value traded | 1.03M GBP | ||
| Zero-volume days | 0.0% | ||
| Income | 44 · Weak | Dividend is small or irregular. | |
| Dividend yield | 2.7% | ||
| Years with dividends | 5 |
Strengths
- Trend: Trading above its long-term averages and near its highs.
- Momentum: Rising faster than most stocks on this exchange.
- Stability (higher is calmer): Calmer than most: low volatility and shallow drawdowns.
Weak spots
- Income: Dividend is small or irregular.
Returns
| 1 week | +3.8% |
|---|---|
| 1 month | +6.4% |
| 3 months | +12.3% |
| 6 months | +19.8% |
| 1 year | +46.2% |
| 3 years | +74.4% |
| 5 years | +19.3% |
Signals
| 50-day / 200-day average | 370.40 / 347.37 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | Yes |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 6.29 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 12 Mar 2026 | GBP 10.7990 |
| 27 Mar 2025 | GBP 9.7000 |
| 14 Mar 2024 | GBP 9.6000 |
| 16 Mar 2023 | GBP 9.5000 |
| 17 Mar 2022 | GBP 9.3000 |
| 18 Mar 2021 | GBP 9.1000 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on London Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.